Sigma Planning Corp Lowers Holdings in Becton, Dickinson and Company (NYSE:BDX)

Posted by Defense World Staff on Apr 6th, 2023

Sigma Planning Corp reduced its stake in shares of Becton, Dickinson and Company (NYSE:BDX – Get Rating) by 1.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,085 shares of the medical instruments supplier’s stock after selling 51 shares during the quarter. Sigma Planning Corp’s holdings in Becton, Dickinson and were worth $1,293,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Brookstone Capital Management increased its holdings in Becton, Dickinson and by 67.3% in the 4th quarter. Brookstone Capital Management now owns 16,623 shares of the medical instruments supplier’s stock valued at $4,311,000 after acquiring an additional 6,687 shares during the last quarter. Ellevest Inc. increased its holdings in shares of Becton, Dickinson and by 196.1% in the third quarter. Ellevest Inc. now owns 767 shares of the medical instruments supplier’s stock worth $171,000 after purchasing an additional 508 shares during the last quarter. Great West Life Assurance Co. Can purchased a new stake in shares of Becton, Dickinson and in the third quarter worth about $50,266,000. My Legacy Advisors LLC boosted its stake in Becton, Dickinson and by 22.0% during the third quarter. My Legacy Advisors LLC now owns 2,217 shares of the medical instruments supplier’s stock valued at $498,000 after buying an additional 400 shares during the last quarter. Finally, Duality Advisers LP purchased a new position in Becton, Dickinson and during the 3rd quarter valued at approximately $5,269,000. Institutional investors own 87.08% of the company’s stock.

Insider Transactions at Becton, Dickinson and

In other news, EVP Richard Byrd sold 1,421 shares of the company’s stock in a transaction dated Friday, February 3rd. The shares were sold at an average price of $248.60, for a total value of $353,260.60. Following the transaction, the executive vice president now directly owns 4,119 shares in the company, valued at $1,023,983.40. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 0.31% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on BDX shares. StockNews.com initiated coverage on Becton, Dickinson and in a report on Thursday, March 16th. They set a “buy” rating on the stock. Evercore ISI lowered their price objective on shares of Becton, Dickinson and from $280.00 to $275.00 and set an “outperform” rating for the company in a research report on Tuesday. Piper Sandler lifted their price objective on shares of Becton, Dickinson and from $245.00 to $260.00 and gave the stock a “neutral” rating in a research note on Thursday, February 2nd. Bank of America upgraded shares of Becton, Dickinson and from a “neutral” rating to a “buy” rating and upped their target price for the company from $250.00 to $290.00 in a research report on Tuesday, January 3rd. Finally, Citigroup upgraded Becton, Dickinson and from a “sell” rating to a “neutral” rating and lifted their price target for the stock from $221.00 to $250.00 in a research report on Monday, December 12th. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $272.44.

Becton, Dickinson and Stock Performance

Shares of NYSE:BDX opened at $251.67 on Thursday. The company has a current ratio of 1.07, a quick ratio of 0.60 and a debt-to-equity ratio of 0.56. Becton, Dickinson and Company has a 12 month low of $215.90 and a 12 month high of $277.29. The company has a market capitalization of $71.45 billion, a price-to-earnings ratio of 47.48, a PEG ratio of 2.61 and a beta of 0.54. The firm’s 50-day moving average is $241.97 and its 200 day moving average is $240.41.

Becton, Dickinson and (NYSE:BDX – Get Rating) last released its earnings results on Thursday, February 2nd. The medical instruments supplier reported $2.98 EPS for the quarter, beating analysts’ consensus estimates of $2.68 by $0.30. Becton, Dickinson and had a return on equity of 13.52% and a net margin of 8.47%. The firm had revenue of $4.59 billion for the quarter, compared to analysts’ expectations of $4.59 billion. During the same quarter in the prior year, the firm posted $3.64 earnings per share. The company’s quarterly revenue was down 2.8% on a year-over-year basis. Research analysts predict that Becton, Dickinson and Company will post 12.19 EPS for the current year.

Becton, Dickinson and Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, March 31st. Shareholders of record on Friday, March 10th were paid a $0.91 dividend. The ex-dividend date was Thursday, March 9th. This represents a $3.64 dividend on an annualized basis and a yield of 1.45%. Becton, Dickinson and’s payout ratio is 68.68%.

Becton, Dickinson and Profile

(Get Rating)

Becton, Dickinson & Co engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery.